Pfizer gains unconditional EU antitrust nod for proposed USD 43 billion Seagen acquisition
"The proposed merger would not raise competition concerns," the EU antitrust watchdog said in a statement.
Brussels: U.S. pharmaceutical company Pfizer has gained unconditional EU antitrust approval for its proposed $43 billion acquisition of cancer drug maker Seagen.
Pfizer announced the deal in March, its largest purchase in a string of recent acquisitions thanks to a once-in-a-lifetime cash windfall from its COVID-19 vaccine and treatment.
The European Commission said the deal would not significantly reduce competition in the 27-country European Union nor would it have a negative impact on prices.
Read also: Pfizer USD 43 billion bid for Seagen to be decided by EU antitrust regulators
"The proposed merger would not raise competition concerns," the EU antitrust watchdog said in a statement.
Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed to destroy cancer while sparing healthy cells.
Read also: EU medicines regulator recommends conditional marketing nod for Pfizer blood cancer therapy
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.